Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

Biogen reported Phase 2 CELIA data showing robust reductions in tau pathology across all diranersen doses and pre-specified cognitive analyses indicating slowed clinical decline, especially at the lowest 60 mg every 24 weeks dose. The study missed its primary endpoint on dose response for CDR-SB at Week 76, but the company said the biomarker and efficacy profile is strong enough to advance diranersen to registrational development. Safety was generally consistent with Phase 1b, though serious adverse events were higher at the top dose.

Analysis

This is the first credible human-data readthrough that tau lowering may be more than a biomarker story, which matters because the market has mostly treated tau programs as “science optionality” rather than a near-term commercial platform. The key second-order effect is not just BIIB rerating on a single asset; it is the repricing of the entire tau franchise and a higher probability that late-stage AD development becomes a multi-modal contest rather than an anti-amyloid monopoly. If regulators accept a biomarker + clinical decline package despite a missed dose-response primary, Biogen may have effectively de-risked a regulatory path that the street had assigned very low probability.

The stronger signal is actually the asymmetry in the readout: the lowest dose looking best is a classic dose-selection problem that can be optimized in registrational studies, while the highest dose’s safety noise gives competitors a clean opening to attack the platform as a narrow-window therapy. That means the next 3-6 months should be about trial design optics, not just headline efficacy; investors will likely focus on whether Biogen can simplify into one dose and avoid a “multiple shots on goal, no clean winner” narrative. Ionis gets only indirect credit here because the economic upside is still mostly buried under Biogen’s commercial and regulatory control.

The contrarian risk is that this becomes a “beautiful phase 2, messy phase 3” setup. Alzheimer’s has repeatedly punished biomarker enthusiasm when the treatment effect must be reproduced in larger, noisier populations, and any hint that benefit is concentrated in a low-dose subgroup will invite skepticism around robustness. Over the next 1-2 weeks the stock can continue to grind higher on sentiment; over 6-18 months the real swing factor is whether endpoint selection and patient enrichment can turn this from a scientific milestone into a registrationally durable label.

Key Decisions for Investors

• Go long BIIB on pullbacks over the next 1-2 sessions; this is a sentiment-driven rerate event with room for another 5-10% as the market digests a plausible registrational path, but size for headline volatility until the full dataset is presented.
• Consider a BIIB/XLV pair trade for 1-3 months: long BIIB against the sector ETF to isolate the idiosyncratic pipeline revaluation while reducing broader biotech beta.
• Buy BIIB call spreads 3-6 months out rather than outright stock if options are liquid; the best payoff is a continuation move into AAIC/medical congresses, but the missed primary endpoint caps near-term multiple expansion.
• Avoid chasing IONS on this release; the value capture is indirect and likely delayed, making it a lower-conviction sympathy trade unless additional royalty/economic detail emerges.
• If BIIB gaps hard on the headline, fade part of the move with a tight stop after the first 48 hours; phase-2 AD enthusiasm often mean-reverts once investors focus on execution risk and subgroup dependence.